List of Excipients in Branded Drug METHYLPREDNISOLONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Quality Care Products LLC	METHYLPREDNISOLONE	methylprednisolone	49999-153	ANHYDROUS LACTOSE
Quality Care Products LLC	METHYLPREDNISOLONE	methylprednisolone	49999-153	CELLULOSE, MICROCRYSTALLINE
Quality Care Products LLC	METHYLPREDNISOLONE	methylprednisolone	49999-153	MAGNESIUM STEARATE
Quality Care Products LLC	METHYLPREDNISOLONE	methylprednisolone	49999-153	SILICON DIOXIDE
Quality Care Products LLC	METHYLPREDNISOLONE	methylprednisolone	49999-153	SODIUM LAURYL SULFATE

Generic Drugs Containing METHYLPREDNISOLONE

Company	Ingredient	NDC	Excipient
Endo USA Inc	methylprednisolone	0603-4593	CELLULOSE, MICROCRYSTALLINE
Endo USA Inc	methylprednisolone	0603-4593	MAGNESIUM STEARATE
Endo USA Inc	methylprednisolone	0603-4593	SODIUM STARCH GLYCOLATE TYPE A POTATO
Sandoz Inc	methylprednisolone	0781-5022	CELLULOSE, MICROCRYSTALLINE
Sandoz Inc	methylprednisolone	0781-5022	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in METHYLPREDNISOLONE?

# Of NDCs	Excipient
28	ANHYDROUS LACTOSE
1	CALCIUM STEARATE
73	CELLULOSE, MICROCRYSTALLINE
19	CROSCARMELLOSE SODIUM
2	HYPROMELLOSE 2910

Methylprednisolone Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Methylprednisolone is a mature corticosteroid with limited core-molecule patent protection and substantial generic competition. Commercial value is concentrated in formulation execution: injectable stability, preservative-free presentation, ready-to-use hospital products, differentiated oral dosage forms, and excipient choices that reduce safety or administration barriers. The strongest opportunities are likely in sterile products, specialty delivery, and supply-chain reliability rather than conventional immediate-release tablets.

What products and dosage forms contain methylprednisolone?

Methylprednisolone is marketed in several chemical and dosage-form configurations. The active pharmaceutical ingredient, salt or ester, route, and excipient system determine the regulatory and commercial strategy.

Product type	Active form	Route	Commercial purpose
Immediate-release tablets	Methylprednisolone	Oral	Acute inflammatory and immunologic conditions
Injectable solution	Methylprednisolone sodium succinate	Intravenous or intramuscular	Rapid systemic corticosteroid treatment
Injectable suspension	Methylprednisolone acetate	Intramuscular or intra-articular	Depot and local anti-inflammatory treatment
Dose packs	Methylprednisolone tablets	Oral	Short tapering regimens
Hospital presentations	Usually sodium succinate	Intravenous or intramuscular	Emergency, inpatient and procedural use

Methylprednisolone is a small-molecule corticosteroid, not a biologic. Biosimilar regulation does not apply. Competition proceeds primarily through abbreviated new drug applications, authorized generics, contract manufacturing and, for differentiated products, potential 505(b)(2) pathways under the Federal Food, Drug, and Cosmetic Act (FDA, 2024a).

What excipients are used in methylprednisolone products?

Excipients vary materially by dosage form and strength. The formulation objective is not the same for an oral tablet, a reconstituted injectable powder and a depot suspension.

Oral methylprednisolone tablets

Reference methylprednisolone tablets use conventional solid-dose excipients, including diluents, disintegrants, lubricants and sweetening or compression aids. FDA labeling for Medrol identifies inactive ingredients such as lactose, corn starch, sucrose and calcium stearate, although exact composition can vary by product and strength (Pfizer, 2023a).

The main excipient risks are:

• Lactose intolerance and dairy-derived excipient concerns.
• Sugar content in patients requiring repeated courses.
• Tablet size and swallowability.
• Dose uniformity across low-strength tablets.
• Moisture sensitivity and physical stability.
• Taste and patient acceptance in pediatric or geriatric use.

A generic developer can create commercial separation through lactose-free, sucrose-free, low-sugar or directly compressible formulations. These changes may have limited clinical value in a single short course but can matter in chronic steroid use, pediatric treatment and hospital formulary selection.

Methylprednisolone sodium succinate injection

Methylprednisolone sodium succinate is designed for parenteral administration and rapid dissolution after reconstitution. The excipient system must control pH, osmolality, chemical degradation, particulate formation and compatibility with diluents and infusion systems.

Critical formulation attributes include:

• Rapid and complete reconstitution.
• Low visible and subvisible particulate burden.
• Chemical stability after reconstitution.
• Compatibility with common infusion solutions.
• Low extractables and leachables from the container closure system.
• Preservative-free presentation where neonatal, pediatric or repeated-dose use requires it.
• Reliable performance in emergency settings.

The Solu-Medrol label describes multiple presentations, including vial and Act-O-Vial configurations. Inactive ingredients and diluent composition can differ by presentation and strength (Pfizer, 2023b). A developer should treat each presentation as a separate formulation and device-combination risk rather than assume that one excipient package transfers across the portfolio.

Methylprednisolone acetate suspension

Methylprednisolone acetate is a poorly water-soluble ester used in depot suspensions. The product requires a controlled particle-size distribution, suspension stability and predictable dose delivery. The formulation typically uses a vehicle, surfactant, tonicity modifier and antimicrobial or preservative system appropriate to the route and container.

Depo-Medrol labeling identifies excipients including polyethylene glycol, polysorbate 80, phosphate salts and sodium chloride, with composition varying by product presentation (Pfizer, 2023c).

The principal technical risks are:

• Particle growth during storage.
• Sedimentation and incomplete redispersion.
• Needle clogging.
• Dose variability after partial settling.
• Local tissue reaction.
• Container compatibility.
• Microbial control in multidose presentations.
• Sterility assurance for intra-articular and intramuscular use.

Suspension performance is a meaningful barrier to entry. A product that meets chemical specifications but produces inconsistent redispersion or injection force can fail clinical usability and procurement evaluation.

What excipient strategy is strongest for methylprednisolone tablets?

The strongest oral strategy is usually a platform approach rather than a novel excipient claim. The developer should prioritize manufacturability, patient segmentation and procurement differentiation.

Lactose-free and sugar-reduced tablets

Lactose-free tablets can target patients with lactose intolerance and institutions that prefer simplified excipient profiles. Replacing lactose and sucrose requires reassessment of compressibility, friability, dissolution, hardness and stability.

Potential replacement systems include:

• Microcrystalline cellulose as a diluent and compression aid.
• Mannitol for a low-sugar or orally disintegrating platform.
• Crospovidone or croscarmellose sodium for rapid disintegration.
• Low-substituted hydroxypropyl cellulose for tablet breakup and compactibility.
• Magnesium stearate or alternative lubricants, subject to dissolution and compatibility testing.

A lactose-free claim has commercial value only if it is supported by consistent labeling and does not introduce a more problematic excipient, such as a high level of polyol that causes gastrointestinal intolerance.

Orally disintegrating and pediatric products

An orally disintegrating tablet, mini-tablet or granule presentation could address pediatric and dysphagia populations. Methylprednisolone is suited to low-dose, high-potency delivery, but taste masking is necessary.

Useful technologies include:

• Mannitol-based rapidly dispersing matrices.
• Ion-exchange resin complexes.
• Coated drug particles.
• Flavors and sweeteners compatible with pediatric use.
• Dry granules for reconstitution.
• Unit-dose oral solutions or suspensions.

The main risks are dose uniformity, palatability, moisture uptake and the regulatory burden associated with a new dosage form. A 505(b)(2) strategy may be relevant where the product relies on a changed route, dosage form or delivery profile supported by published data and bridging studies. A conventional bioequivalence pathway may be available for a therapeutically equivalent tablet, subject to FDA requirements.

Dose-pack optimization

Methylprednisolone dose packs are commercially recognizable but operationally vulnerable to packaging errors, tablet-count errors and patient confusion. Opportunities include:

• Calendarized blister packaging.
• Clear taper instructions.
• Unit-dose hospital packaging.
• Child-resistant and senior-friendly designs.
• Electronic medication-adherence integration.
• Dose packs using lactose-free or low-sugar tablets.

The packaging configuration may provide trade dress or design differentiation, but it generally does not create durable pharmaceutical exclusivity by itself.

What excipient strategy is strongest for injectable methylprednisolone?

Injectable products offer the most defensible technical opportunities because sterile manufacturing, reconstitution behavior and container closure performance raise development barriers.

Ready-to-use sodium succinate injection

A ready-to-use solution could reduce emergency preparation time and medication errors compared with a powder requiring reconstitution. Commercial targets include emergency departments, ambulances, operating rooms and infusion centers.

Potential presentations include:

• Prefilled syringes.
• Pharmacy bulk packages.
• Ready-to-use bags.
• Dual-chamber containers.
• Small-volume vials with simplified preparation.

The formulation must maintain stability without excessive preservative use. A ready-to-use product may require a new NDA or 505(b)(2) application rather than a standard ANDA, depending on the reference product and the proposed formulation.

Preservative-free presentations

Preservative-free methylprednisolone sodium succinate may have value in neonates, children, ophthalmic-adjacent procedures and patients exposed to repeated parenteral dosing. The commercial benefit is strongest where institutional protocols restrict benzyl alcohol or other preservatives.

The tradeoff is higher packaging and manufacturing cost. Single-dose vials, prefilled syringes and small-volume ampoules can reduce contamination risk but increase unit cost and packaging complexity.

Dual-chamber and closed-system delivery

A dual-chamber vial can separate dry drug from diluent until use. This approach can improve shelf stability and reduce preparation steps. It also creates device, human-factors and combination-product requirements.

Commercial advantages include:

• Fewer reconstitution steps.
• Reduced needle manipulation.
• Faster emergency administration.
• Better dose preparation consistency.
• Lower risk of selecting the wrong diluent.

The principal barriers are device reliability, fill-finish capacity, extractables and leachables, human-factors validation and higher capital requirements.

What formulation patents could protect a methylprednisolone product?

Methylprednisolone’s core composition and principal clinical uses are old. The commercial patent opportunity is therefore more likely to involve a specific formulation or delivery system than the active ingredient.

Potential claim categories include:

Claim category	Potentially protectable subject matter	Commercial strength
Solid oral dosage form	Excipient ratios, disintegration profile, dissolution control	Low to moderate
Taste-masked product	Coated particles, resin complex or flavor system	Moderate
Oral suspension	Particle-size control, sedimentation and redispersion	Moderate
Injectable solution	pH, buffer, concentration and stability window	Moderate if technically unexpected
Sterile powder	Lyophilization cycle and cake structure	Moderate
Depot suspension	Particle-size distribution and redispersion	Moderate to strong if linked to performance
Container closure	Syringe, dual-chamber vial or delivery system	Moderate
Manufacturing process	Sterilization, milling, aseptic filling or suspension processing	Moderate, subject to enforceability

A formulation patent must show more than routine optimization. Narrow excipient-range claims face vulnerability if the claimed parameters are predictable and the prior art discloses the same ingredients. The strongest patent position would link composition to a measurable technical result, such as improved reconstitution time, reduced aggregation, controlled particle growth, reduced injection force or extended stability.

What is the Orange Book and exclusivity status of methylprednisolone?

Methylprednisolone is a legacy small-molecule product with extensive generic availability. Its original composition-of-matter protection and historic regulatory exclusivities expired decades ago. Current commercial analysis should distinguish among the tablet, sodium succinate injection and acetate suspension products because each may have separate FDA reference listings and patent records.

The FDA Orange Book identifies approved drug products, therapeutic equivalence evaluations and, where applicable, listed patents and exclusivity information (FDA, 2024b). For mature methylprednisolone products, the primary competitive issue is generally not basic molecule exclusivity. It is whether a specific branded or reformulated product has current formulation, device or method-of-use listings.

Paragraph IV challenge risk

A conventional generic methylprednisolone tablet or injectable is exposed to Paragraph IV risk only to the extent that an Orange Book-listed patent remains active and relevant. Because the core products are old, a new entrant is more likely to confront:

• Product-specific formulation patents.
• Device or container patents.
• Method-of-use patents.
• Patent claims covering a branded reformulation.
• Regulatory exclusivity associated with a newer dosage form.

For the legacy immediate-release tablet, the principal risk is price erosion rather than patent litigation. For a newly differentiated injectable, the sponsor may create its own patent estate but also attract Paragraph IV challenges after ANDA filings.

When does methylprednisolone lose exclusivity?

The active ingredient lost meaningful exclusivity long ago, and generic methylprednisolone products are widely marketed. There is no biosimilar exclusivity period because methylprednisolone is not a biologic.

A new formulation can receive separate regulatory exclusivity depending on the approval pathway and product characteristics. Potential categories include:

• Three-year exclusivity for certain applications containing new clinical investigations essential to approval.
• Five-year new chemical entity exclusivity, generally unavailable for an old active ingredient unless the regulatory product qualifies under a distinct statutory basis.
• Orphan-drug exclusivity for a qualifying orphan indication.
• Pediatric exclusivity, if awarded through FDA mechanisms.

The practical exclusivity value of a methylprednisolone reformulation is likely to depend more on patent scope and switching friction than on statutory exclusivity.

Which companies compete in the methylprednisolone market?

Competition includes the historical reference-product sponsors Pfizer and its relevant legacy brands, generic manufacturers, injectable specialists and contract development and manufacturing organizations.

The competitive field is divided into four groups:

1. Low-cost oral tablet manufacturers.
2. Hospital injectable suppliers.
3. Specialty sterile manufacturers.
4. Developers of differentiated delivery systems.

Hospitals often evaluate injectable suppliers on shortage history, fill-finish quality, delivery reliability, vial configuration and total preparation burden. A supplier with a slightly higher unit price can win business if it reduces pharmacy labor, medication errors or product wastage.

What commercial opportunities exist for methylprednisolone?

Hospital injectable supply

Sterile injectable shortages create the clearest near-term opportunity. A reliable sodium succinate supplier can compete through:

• Multiple vial sizes.
• Preservative-free products.
• Shorter reconstitution time.
• Ready-to-use configurations.
• Dual sourcing and domestic fill-finish.
• Stable inventory during competitor shortages.

The product is mature, so procurement contracts and manufacturing reliability may matter more than brand promotion.

Specialty depot suspension

Methylprednisolone acetate suspension remains relevant in musculoskeletal and inflammatory care. Opportunities include improved syringeability, consistent redispersion and differentiated packaging for office-based administration.

A developer must manage route-specific safety, particulate characterization and injection-device compatibility. Any claim of improved local tolerability requires credible clinical support.

Pediatric and dysphagia formulations

Liquid, mini-tablet and orally disintegrating formulations could address a practical gap in administration. The opportunity is strongest where the product improves dose accuracy and adherence without relying on problematic preservatives or excessive sweeteners.

Emerging-market products

Geographic opportunities exist where branded products are expensive, injectable supply is inconsistent or local manufacturers lack sterile capabilities. Regulatory strategy must account for country-specific excipient restrictions, pharmacopeial requirements, cold-chain expectations and local bioequivalence rules.

A single global formulation may not be optimal. Preservative-free products, ampoules and multidose presentations can face different acceptance standards across jurisdictions.

How strong is the methylprednisolone patent estate?

The core patent estate is weak because the molecule and principal dosage forms are long established. A new formulation estate can be moderately strong if it combines:

• Narrow, reproducible composition claims.
• A demonstrated performance benefit.
• Process claims difficult to design around.
• Device or container claims.
• Claims covering multiple strengths and presentations.
• Supporting clinical or human-factors data.

The weakest strategy is a broad claim to conventional excipients without a demonstrated technical effect. The strongest strategy is a layered estate covering composition, process, container and use, supported by stability and administration data.

What generic launch scenarios exist for methylprednisolone?

Conventional tablet launch

This is the lowest-barrier scenario. Entry is likely to produce rapid price erosion, multiple suppliers and limited durable differentiation. A generic sponsor needs low-cost production, dependable API supply and efficient packaging.

Differentiated oral launch

A lactose-free, taste-masked, orally disintegrating or pediatric product can support higher pricing if it qualifies for a differentiated regulatory pathway and earns formulary or specialty-pharmacy adoption.

Injectable shortage-driven launch

A new sodium succinate injectable can obtain commercial traction through supply reliability and hospital contracting. The main execution risks are sterile capacity, FDA inspection readiness, container closure performance and post-approval manufacturing consistency.

Depot suspension launch

The acetate suspension category has greater technical complexity than tablets. A product with better redispersion, lower injection force or more convenient packaging could achieve modest premium pricing, but clinical and regulatory evidence requirements are higher.

What manufacturing and IP barriers affect methylprednisolone?

The highest barriers are associated with sterile manufacturing and suspension control.

Key barriers include:

• Access to qualified sterile fill-finish capacity.
• Aseptic process validation.
• Sterilizing filtration or terminal sterilization suitability.
• Control of particulate matter.
• Suspension milling and particle-size control.
• Stability-indicating analytical methods.
• Container closure integrity.
• Extractables and leachables testing.
• Reliable API and ester/salt supply.
• FDA inspection and quality-system performance.

Oral tablets can be manufactured by many suppliers, making cost and scale decisive. Injectable and depot products require specialized equipment, validated processes and stronger quality oversight.

Key Takeaways

• Methylprednisolone has little remaining core-molecule exclusivity and no biosimilar barrier.
• Oral tablet competition is largely a price and supply-chain business.
• The strongest formulation opportunities involve preservative-free injections, ready-to-use delivery, pediatric products and depot suspension performance.
• Excipients can support differentiation, but conventional excipient substitutions rarely create strong patent protection without unexpected technical effects.
• Injectable products have higher development barriers and better potential for commercial defensibility.
• Orange Book analysis must be performed separately for tablets, sodium succinate injections and acetate suspensions.
• Hospital procurement value depends heavily on reconstitution time, packaging, shortage resilience and sterile manufacturing reliability.
• A layered patent estate should cover composition, process, container and use where the formulation supports measurable advantages.

FAQs

Can methylprednisolone be reformulated as an extended-release tablet?

Yes, but an extended-release product would require a distinct release mechanism, pharmacokinetic profile and clinical or bioequivalence strategy. The regulatory pathway would depend on the reference product and the extent of formulation change.

Is a lactose-free methylprednisolone tablet commercially attractive?

It can be attractive in pediatric, chronic-use and institutional markets. The opportunity is strongest when the product also improves swallowability, disintegration or packaging convenience.

Can methylprednisolone sodium succinate be sold in a prefilled syringe?

Potentially. The sponsor would need to establish chemical stability, sterility, syringe compatibility, extractables and leachables, dose accuracy, container closure integrity and human-factors performance.

Does methylprednisolone have a meaningful biosimilar market?

No. Methylprednisolone is a small molecule. Competition is based on generic equivalence, reformulation, sterile manufacturing and delivery technology rather than biosimilar approval.

What is the most defensible methylprednisolone product concept?

A preservative-free, ready-to-use sodium succinate injectable with validated stability and reduced preparation steps is generally more defensible than another conventional tablet. A second strong concept is a pediatric, taste-masked or orally disintegrating product supported by a clear administration advantage.

References

1. Food and Drug Administration. (2024a). Abbreviated new drug application (ANDA). U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. Food and Drug Administration. (2024c). Inactive ingredient database. U.S. Department of Health and Human Services.

4. Pfizer Inc. (2023a). Medrol (methylprednisolone tablets) prescribing information.

5. Pfizer Inc. (2023b). Solu-Medrol (methylprednisolone sodium succinate for injection) prescribing information.

6. Pfizer Inc. (2023c). Depo-Medrol (methylprednisolone acetate injectable suspension) prescribing information.

7. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.